XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. Related: Study Dispels Claim that COVID-19-Causing Coronavirus is Lab-Engineered. So studying the genetics of the current coronavirus strain remains important.

RNA 98

RNA Protein Genome Genomics 98

The Pharma Data

JANUARY 4, 2021

The UC Santa Barbara research uses a method that addresses not only antibiotic overuse, but also the containment of genetically modified organisms (GMOs). “If The process described in the research was previously developed by a former graduate student research in O’Malley’s lab, Justin Yoo.

Bacteria 52

Bacteria Engineer Genetics Genetic Engineering 52

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 – that is worrying health officials around the world. . 1 mutations, as well as variants from the UK and South Africa.

Vaccination 66

Vaccination Vaccine Genetic Engineering Engineer 66

XTalks

JANUARY 2, 2024

Filsuvez topical gel is a sterile botanical drug product designed for topical use, containing birch triterpenes within an oil base. a biotech company specializing in the development and commercialization of genetic medicines for rare diseases, announced FDA approval for Vyjuvek for the treatment of DEB.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

pharmaphorum

APRIL 26, 2022

Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology.

Containment 115

Containment Production Development Immune Response 115

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. “The

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

MARCH 10, 2023

But with Skyclarys (omaveloxolone), the first and only drug to treat Friedreich’s ataxia in patients aged 16 years and older, Reata Pharmaceuticals has developed a new treatment option to improve neurological function. Friedreich’s ataxia is the most common type of hereditary ataxia affecting one in 50,000 people in the US.

FDA Approval 52

FDA Approval Engineer Clinical Trials Clinical Trials 52

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Drug Discovery World

OCTOBER 26, 2022

A new method to study the proteins released by cells, which could lead to new biomarkers for diseases including cancer, has been developed by scientists at the Francis Crick Institute and Imperial College London. . The researchers genetically modify the cell type they want to study, so that only this type adds the sugar to its proteins.

Protein 52

Protein Genetics Containment Research 52

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). The agencies also have different requirements for the selection of healthy donors in the development of allogeneic cell therapies. By 2030, it’s expected to more than double, to $34.3

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

The Pharma Data

NOVEMBER 27, 2020

Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, announced today that the U.S. With this approval, Imcivree becomes the first-ever FDA approved therapy for these rare genetic diseases of obesity. BOSTON, Nov.

FDA Approval 52

FDA Approval Genetic Disease Genetics Clinical Trials 52

XTalks

MAY 7, 2021

Glenn, president of research and development at Novavax, in a news release. “It It also demonstrates that ongoing evaluation of COVID-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inform vaccine development and use.”. Despite the less then stellar efficacy posted against B.1.351

Protein 97

Protein Vaccination Vaccine Trials 97

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. For more information, visit [link].

Manufacturing 52

Manufacturing Packaging Packaging Production 52

The Pharma Data

MARCH 23, 2022

The major challenge in developing drugs directly against Ebola virus polymerase is that scientists have not solved its atomic structure. Early in infection, it appears that host cellular proteins are in defense mode against Ebola virus polymerase and the viral genetic material.

Protein 52

Protein Genome Genomics Research 52

XTalks

NOVEMBER 23, 2020

Developed by researchers at the University of Oxford, the COVID vaccine is an adenovirus vector-based vaccine derived from chimpanzees that contains a genetically engineered virus that causes the common cold in chimpanzees, along with the spike protein of the SARS-CoV-2 coronavirus.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

The Pharma Data

MAY 6, 2021

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Containment 52

Containment Production Development Engineer 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

JULY 27, 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. executive vice president of Research and Development at Amgen. billion in cash. Reese, M.D.,

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

APRIL 22, 2023

Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A. ” Mitragotri is also the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at SEAS.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

The Pharma Data

JANUARY 19, 2021

Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 CAMBRIDGE, Mass., Forward-Looking Statements.

Gene Expression 40

Gene Expression Containment Genetics Sales 40

The Pharma Data

APRIL 18, 2022

Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari. We are proud to contribute to the development of Nuvaxovid and to manufacture the vaccine at our Hikari facilities, continuing our commitment to the COVID-19 public health response in Japan.”.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

We are encouraged by the early evidence of TSHA-105’s disease-modifying approach and believe these designations will help us potentially accelerate the development of this exciting program. Taysha’s commitment to developing a potentially life-changing gene therapy for SLC13A5 deficiency is greatly welcomed by our patient community.”.

Gene Therapy 52

Gene Therapy Gene Drugs Production 52

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.

Genetics 111

Genetics Vaccination Vaccine DNA 111

The Pharma Data

APRIL 27, 2021

Takeda is committed to continuing research and development in EGFR Exon20 insertion+ mNSCLC with the hope of introducing a targeted treatment option for the approximately 30,000 patients diagnosed with the disease worldwide each year, including 3,000 in the U.S. For more information, visit [link]. Forward-Looking Statements.

Drugs 52

Drugs FDA Approval Production Trials 52

Roots Analysis

AUGUST 31, 2023

Further, the transcription factors contain two molecular domains, the DNA binding domain and the activation domain. Moreover, some transcription factors contain additional domains, such as ligand binding domain in order to interact with chemical signals.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

XTalks

AUGUST 10, 2021

The test was developed by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Massachusetts Institute of Technology (MIT) and several Boston area hospitals. However, unprocessed saliva contains enzymes that degrade various molecules, which can lead to a high rate of false positives.

RNA 105

RNA Containment DNA Engineer 105

The Pharma Data

DECEMBER 20, 2020

This announcement marks continued progress on our commitment to simplify our global portfolio and remain focused on investing in our growth drivers, and research and development pipeline,” said Costa Saroukos, Chief Financial Officer, Takeda. “We We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Sales 40

Sales Production Marketing Containment 40

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

AUGUST 10, 2022

Finally, in 2017, after years of improving T cell engineering techniques, the first chimeric antigen receptor (CAR) T cell therapy received FDA approval. Developing the first CAR T cell therapy. To overcome this evasion tactic, the CAR protein was developed to recognise other markers on cancer cells.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Rapid and accurate DNA synthesis .

DNA 98

DNA Drugs Antibody Engineer 98

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

pharmaphorum

JANUARY 3, 2023

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. Epigenetic Editing with CRISPR. pyogenes dCas9.

DNA 98

DNA Gene Gene Silencing Genome 98